Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis

Internal Medicine

Volumn 49, Issue 21, 2010, Pages 2309-2312

  Yagi, Shusuke ^a   Akaike, Masashi ^a   Iwase, Takashi ^a   Kusunose, Kenya ^a   Niki, Toshiyuki ^a   Yamaguchi, Koji ^a   Koshiba, Kunihiko ^a   Yoshida, Sumiko ^a   Sumitomo Ueda, Yuka ^a   Aihara, Ken ichi ^a   Hirata, Yoichiro ^a   Dagvasumberel, Munkhbaatar ^a   Taketani, Yoshio ^a   Tomita, Noriko ^a   Yamada, Hirotsugu ^a   Soeki, Takeshi ^a   Wakatsuki, Tetsuzo ^a   Matsumoto, Toshio ^a   Sata, Masataka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Endothelin 1; Flow mediated dilation; Pulmonary arterial remodeling; Stress echocardiography

Indexed keywords

BOSENTAN; PROSTAGLANDIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE DURATION; DRUG DOSE INCREASE; DYSPNEA; EXERCISE TEST; FEMALE; FINGER ULCER; HUMAN; LUNG ARTERY PRESSURE; PERIPHERAL ISCHEMIA; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT RESPONSE; ULCER; WALKING;

EXERCISE; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SULFONAMIDES;

EID: 78249242071     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3812     Document Type: Article

References (13)

1. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123: 344- 350, 2003.
2. Biondi ML, Marasini B, Bassani C, Agastoni A. Increased plasma endothelin levels in patients with Raynaud's phenomenon. N Engl J Med 324: 1139-1140, 1991.
3. Yamane K, Miyauchi T, Suzuki N, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 19: 1566-1571, 1992.
4. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54: S78-S84, 2009.
5. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436, 2004.
6. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50: 3985-3993, 2004.
7. Dhillon S. Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis. Drugs 69: 2005- 2024, 2009.
8. Crosswhite P, Sun Z. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens 28: 201-212, 2010.
9. Jasmin JF, Lucas M, Cernacek P, Dupuis J. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 103: 314-318, 2001.
10. Sfikakis PP, Papamichael C, Stamatelopoulos KS, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 56: 1985-1993, 2007.
11. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30: 2493- 2537, 2009.
12. Alkotob ML, Soltani P, Sheatt MA, et al. Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. Chest 130: 176-181, 2006.
13. Collins N, Bastian B, Quiqueree L, Jones C, Morgan R, Reeves G. Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I). Eur J Echocardiogr 7: 439-446, 2006.